Renal transplantation in systemic amyloidosis - Importance of amyloid fibril type and precursor protein abundance

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 433-441

  Pinney, J H ^a   Lachmann, H J ^a   Sattianayagam, P T ^a   Gibbs, S D J ^a   Wechalekar, A D ^a   Venner, C P ^a   Whelan, C J ^a   Gilbertson, J A ^a   Rowczenio, D ^a   Hawkins, P N ^a   Gillmore, J D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Amyloidosis; clone; precursor protein; serum amyloid A protein; survival

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; FIBRINOGEN; LYSOZYME; PROTEIN PRECURSOR;

ADULT; AMYLOIDOSIS; ARTICLE; CLONE; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TREATMENT OUTCOME;

ADULT; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; APOLIPOPROTEIN A-I; BIOPSY; DATABASES, FACTUAL; FEMALE; FIBRINOGEN; GRAFT SURVIVAL; GREAT BRITAIN; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873098366     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04326.x     Document Type: Article

References (34)

1. Westermark P, Araki S, Benson MD, et al. Nomenclature of amyloid fibril proteins. Amyloid: Int J Exp Clin Invest 1999; 6: 63-66.
2. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B,. Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int 2008; 74: 218-222.
3. Dember LM., Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458-3471.
4. Kyle RA, Greipp PR, O'Fallon WM,. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220-224.
5. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371.
6. Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009; 20: 444-451.
7. Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 2006; 6: 2342-2347.
8. Benson MD., Ostertag revisited: The inherited systemic amyloidoses without neuropathy. Amyloid 2005; 12: 75-87.
9. Sattianayagam PT, Gibbs SD, Rowczenio D, et al. Hereditary lysozyme amyloidosis-phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 2011;.
10. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
11. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN,. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29.
12. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal AL amyloidosis following chemotherapy. J Clin Oncol 2011; 29: 674-681.
13. Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB,. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109: 1971-1974.
14. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001; 71: 986-992.
15. Gillmore JD, Booth DR, Rela M, et al. Curative hepatorenal transplantation for systemic amyloidosis associated with fibrinogen a-chain Glu526Val in an English family. In:, Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. Pearl River, New York: Parthenon Publishing, 1999, pp. 336-338.
16. Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A alpha-chain amyloidosis: Phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 2010; 115: 2998-3007.
17. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-18.
18. Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M,. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2010; 29: 1395-1401.
19. Kofman T, Grimbert P, Poitrine FC, et al. Renal transplantation in patients with AA amyloidosis nephropathy: Results from a French Multicenter study. Am J Transplant 2011; 11: 2423-2431.
20. Puchtler H, Sweat F, Levine M,. On the binding of Congo red by amyloid. J Histochem Cytochem 1962; 10: 355-364.
21. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, et al. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991; 89: 137-141.
22. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79: 319-328.
23. Schmidt P, Kopsa H, Balcke P, Zazgornik J, Pils P, Hysek H,. Behaviour of serum and urinary lysozyme after renal transplantation (author's transl). Wien Klin Wochenschr 1977; 89: 238-242.
24. Hawkins PN., Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11: 649-655.
25. Gillmore JD, Madhoo S, Pepys MB, Hawkins PN,. Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy. Nucl Med Commun 2000; 21: 735-740.
26. 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998; 42: 727-734.
27. Pasternack A, Ahonen J, Kuhlback B,. Renal transplantation in 45 patients with amyloidosis. Transplantation 1986; 42: 598-601.
28. Sherif AM, Refaie AF, Sobh MA, Mohamed NA, Sheashaa HA, Ghoneim MA,. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 2003; 42: 370-375.
29. Emiroglu R, Basaran O, Pehlivan S, et al. Effect of amyloidosis on long-term survival in kidney transplantation. Transplant Proc 2005; 37: 2967-2968.
30. Gillmore JD, Booth DR, Rela M, et al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. QJ Med 2000; 93: 269-275.
31. Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB,. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109: 1971-1974.
32. Pepys MB,. Amyloidosis. Annu Rev Med 2006; 57: 223-241.
33. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
34. Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 2003; 21: 343-346.